|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PURB |
Gene summary for PURB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PURB | Gene ID | 5814 |
| Gene name | purine rich element binding protein B | |
| Gene Alias | PURBETA | |
| Cytomap | 7p13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q96QR8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5814 | PURB | LZE4T | Human | Esophagus | ESCC | 1.56e-02 | 1.67e-02 | 0.0811 |
| 5814 | PURB | LZE8T | Human | Esophagus | ESCC | 1.34e-07 | -7.57e-02 | 0.067 |
| 5814 | PURB | LZE20T | Human | Esophagus | ESCC | 9.20e-05 | -6.76e-02 | 0.0662 |
| 5814 | PURB | LZE22T | Human | Esophagus | ESCC | 2.76e-02 | 1.61e-01 | 0.068 |
| 5814 | PURB | LZE24T | Human | Esophagus | ESCC | 1.75e-12 | 1.01e-01 | 0.0596 |
| 5814 | PURB | LZE21T | Human | Esophagus | ESCC | 1.38e-04 | 2.29e-02 | 0.0655 |
| 5814 | PURB | P1T-E | Human | Esophagus | ESCC | 1.33e-11 | 1.11e-01 | 0.0875 |
| 5814 | PURB | P2T-E | Human | Esophagus | ESCC | 8.19e-22 | 3.55e-01 | 0.1177 |
| 5814 | PURB | P4T-E | Human | Esophagus | ESCC | 9.08e-09 | 1.33e-01 | 0.1323 |
| 5814 | PURB | P5T-E | Human | Esophagus | ESCC | 2.05e-09 | -1.31e-01 | 0.1327 |
| 5814 | PURB | P8T-E | Human | Esophagus | ESCC | 1.64e-15 | 1.38e-01 | 0.0889 |
| 5814 | PURB | P9T-E | Human | Esophagus | ESCC | 1.33e-19 | 1.37e-01 | 0.1131 |
| 5814 | PURB | P10T-E | Human | Esophagus | ESCC | 7.43e-21 | 3.35e-01 | 0.116 |
| 5814 | PURB | P11T-E | Human | Esophagus | ESCC | 5.14e-05 | 1.61e-01 | 0.1426 |
| 5814 | PURB | P12T-E | Human | Esophagus | ESCC | 1.53e-16 | 1.15e-01 | 0.1122 |
| 5814 | PURB | P15T-E | Human | Esophagus | ESCC | 4.84e-07 | 1.32e-01 | 0.1149 |
| 5814 | PURB | P16T-E | Human | Esophagus | ESCC | 1.29e-19 | 2.35e-01 | 0.1153 |
| 5814 | PURB | P17T-E | Human | Esophagus | ESCC | 2.65e-10 | 2.68e-01 | 0.1278 |
| 5814 | PURB | P20T-E | Human | Esophagus | ESCC | 3.23e-06 | -6.40e-02 | 0.1124 |
| 5814 | PURB | P21T-E | Human | Esophagus | ESCC | 1.48e-14 | 1.47e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:1903706110 | Esophagus | ESCC | regulation of hemopoiesis | 201/8552 | 367/18723 | 2.60e-04 | 1.58e-03 | 201 |
| GO:0045637111 | Esophagus | ESCC | regulation of myeloid cell differentiation | 118/8552 | 210/18723 | 1.35e-03 | 6.43e-03 | 118 |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
| GO:190370618 | Oral cavity | OSCC | regulation of hemopoiesis | 180/7305 | 367/18723 | 5.16e-05 | 4.30e-04 | 180 |
| GO:004563720 | Oral cavity | OSCC | regulation of myeloid cell differentiation | 106/7305 | 210/18723 | 4.58e-04 | 2.76e-03 | 106 |
| GO:003009918 | Prostate | BPH | myeloid cell differentiation | 115/3107 | 381/18723 | 2.22e-11 | 1.51e-09 | 115 |
| GO:190370616 | Prostate | BPH | regulation of hemopoiesis | 97/3107 | 367/18723 | 1.01e-06 | 1.83e-05 | 97 |
| GO:004563718 | Prostate | BPH | regulation of myeloid cell differentiation | 62/3107 | 210/18723 | 1.99e-06 | 3.30e-05 | 62 |
| GO:003009919 | Prostate | Tumor | myeloid cell differentiation | 120/3246 | 381/18723 | 6.96e-12 | 5.62e-10 | 120 |
| GO:004563719 | Prostate | Tumor | regulation of myeloid cell differentiation | 67/3246 | 210/18723 | 1.71e-07 | 4.25e-06 | 67 |
| GO:190370617 | Prostate | Tumor | regulation of hemopoiesis | 103/3246 | 367/18723 | 1.78e-07 | 4.38e-06 | 103 |
| GO:003009929 | Skin | cSCC | myeloid cell differentiation | 146/4864 | 381/18723 | 6.38e-08 | 1.61e-06 | 146 |
| GO:190370626 | Skin | cSCC | regulation of hemopoiesis | 120/4864 | 367/18723 | 2.23e-03 | 1.32e-02 | 120 |
| GO:004563727 | Skin | cSCC | regulation of myeloid cell differentiation | 73/4864 | 210/18723 | 2.84e-03 | 1.59e-02 | 73 |
| GO:190370627 | Thyroid | HT | regulation of hemopoiesis | 47/1272 | 367/18723 | 2.05e-05 | 4.68e-04 | 47 |
| GO:003009930 | Thyroid | HT | myeloid cell differentiation | 45/1272 | 381/18723 | 2.07e-04 | 3.00e-03 | 45 |
| GO:004563728 | Thyroid | HT | regulation of myeloid cell differentiation | 28/1272 | 210/18723 | 4.77e-04 | 5.78e-03 | 28 |
| GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PURB | SNV | Missense_Mutation | novel | c.564N>T | p.Lys188Asn | p.K188N | Q96QR8 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
| PURB | SNV | Missense_Mutation | c.745G>A | p.Glu249Lys | p.E249K | Q96QR8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PURB | SNV | Missense_Mutation | rs866349527 | c.827N>T | p.Ala276Val | p.A276V | Q96QR8 | protein_coding | tolerated(0.87) | probably_damaging(0.918) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PURB | SNV | Missense_Mutation | rs568851952 | c.890N>T | p.Gly297Val | p.G297V | Q96QR8 | protein_coding | tolerated_low_confidence(0.18) | probably_damaging(0.972) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PURB | SNV | Missense_Mutation | rs770929116 | c.187G>A | p.Glu63Lys | p.E63K | Q96QR8 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-44-2662-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Other, specify in notesGSK Mage Vaccine Study | rec | PD |
| PURB | SNV | Missense_Mutation | c.628N>T | p.Gly210Cys | p.G210C | Q96QR8 | protein_coding | tolerated(0.07) | possibly_damaging(0.784) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| PURB | SNV | Missense_Mutation | c.856N>A | p.Gln286Lys | p.Q286K | Q96QR8 | protein_coding | tolerated(0.19) | benign(0.07) | TCGA-62-A46U-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR | |
| PURB | SNV | Missense_Mutation | rs752452775 | c.611N>T | p.Pro204Leu | p.P204L | Q96QR8 | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-99-8032-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PURB | deletion | In_Frame_Del | novel | c.933_935delNNN | p.Glu311del | p.E311del | Q96QR8 | protein_coding | TCGA-58-8392-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| PURB | SNV | Missense_Mutation | novel | c.655N>T | p.Leu219Phe | p.L219F | Q96QR8 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-CN-6023-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | erbitux | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |